|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Adams Respiratory Therapeutics, Inc. (ARXT), a manufacturer of prescription respiratory medications. |
|---|---|
| Transferring Party | Cornerstone BioPharma, Inc., a manufacturer of prescription and OTC drugs. |
| Sector | Biopharmaceuticals |
| Date | February 15, 2005 |
| Analysis Cornerstone will transfer the Humibid product line to Adams, and in return Adams will transfer their AlleRx line to Cornerstone. This Deal will add to Adams portfolio of prescription drugs. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |